therapeutic agent
Recently Published Documents


TOTAL DOCUMENTS

2644
(FIVE YEARS 820)

H-INDEX

73
(FIVE YEARS 14)

2022 ◽  
Vol 205 ◽  
pp. 108914
Author(s):  
Cristina Alonso ◽  
Valentina Satta ◽  
Paula Díez-Gutiérrez ◽  
Javier Fernández-Ruiz ◽  
Onintza Sagredo

2022 ◽  
Vol 14 (1) ◽  
pp. 110-123
Author(s):  
Norio Uemura ◽  
Hiromitsu Hayashi ◽  
Hideo Baba

Pharmaceutics ◽  
2022 ◽  
Vol 14 (1) ◽  
pp. 186
Author(s):  
Guan-Xuan Wu ◽  
Chun-Yu Chen ◽  
Chun-Shien Wu ◽  
Lain-Chyr Hwang ◽  
Shan-Wei Yang ◽  
...  

Osteoarthritis (OA) is a joint disorder characterized by the progressive degeneration of articular cartilage. The phenotype and metabolism behavior of chondrocytes plays crucial roles in maintaining articular cartilage function. Chondrocytes dedifferentiate and lose their cartilage phenotype after successive subcultures or inflammation and synthesize collagen I and X (COL I and COL X). Farnesol, a sesquiterpene compound, has an anti-inflammatory effect and promotes collagen synthesis. However, its potent restoration effects on differentiated chondrocytes have seldom been evaluated. The presented study investigated farnesol’s effect on phenotype restoration by examining collagen and glycosaminoglycan (GAG) synthesis from dedifferentiated chondrocytes. The results indicated that chondrocytes gradually dedifferentiated through cellular morphology change, reduced expressions of COL II and SOX9, increased the expression of COL X and diminished GAG synthesis during four passages of subcultures. Pure farnesol and hyaluronan-encapsulated farnesol nanoparticles promote COL II synthesis. GAG synthesis significantly increased 2.5-fold after a farnesol treatment of dedifferentiated chondrocytes, indicating the restoration of chondrocyte functions. In addition, farnesol drastically increased the synthesis of COL II (2.5-fold) and GAG (15-fold) on interleukin-1β-induced dedifferentiated chondrocytes. A significant reduction of COL I, COL X and proinflammatory cytokine prostaglandin E2 was observed. In summary, farnesol may serve as a therapeutic agent in OA treatment.


Author(s):  
Maliheh Hadisi ◽  
Naser Vosoughi ◽  
Hassan Yousefnia ◽  
Ali Bahrami-Samani ◽  
Samaneh Zolghadri ◽  
...  

2022 ◽  
Vol 23 (2) ◽  
pp. 865
Author(s):  
Jinsoo Kim ◽  
Dohee Ahn ◽  
Sang J. Chung

Depletion of protein phosphatase-1 catalytic subunit beta (PPP1CB), a serine/threonine protein phosphatase and potent adipogenic activator, suppresses the differentiation of 3T3-L1 preadipocytes into mature adipocytes. Therefore, PPP1CB is considered as a potential therapeutic target for obesity. We screened 1033 natural products for PPP1CB inhibitors and identified chebulinic acid, which is abundantly present in the seeds of Euphoria longana and fruits of Terminalia chebula. Chebulinic acid strongly inhibited the hydrolysis of 6,8-difluoro-4-methylumbelliferyl phosphate by PPP1CB (IC50 = 300 nM) and demonstrated potent antiadipogenic effects in 3T3-L1 preadipocytes in a concentration-dependent manner. Additional studies have demonstrated that chebulinic acid suppresses early differentiation by downregulating key transcription factors that control adipogenesis in 3T3-L1 cells. These results suggested that chebulinic acid may be a potential therapeutic agent for treating obesity by inhibiting PPP1CB activity.


2022 ◽  
Vol 12 ◽  
Author(s):  
Hisashi Sasaki ◽  
Jun Miyata ◽  
Akiko Irie ◽  
Ayako Kuwata ◽  
Yuji Kouzaki ◽  
...  

Eosinophilic bronchiolitis is a rare allergic disorder caused by eosinophilic inflammation in the bronchioles of the lungs. An effective treatment strategy is needed in cases resistant to steroids. However, its pathophysiology remains unclear owing to the limited number of cases. We herein present the case of a 31-year-old man who experienced eosinophilic bronchiolitis with eosinophil ETosis (EETosis) in the mucus plugs. The patient was diagnosed with asthma. His respiratory symptoms worsened with eosinophilia when treated with the standard asthma regimen, including inhaled corticosteroids, long-acting β2-agonist, long-acting muscarinic antagonist, and leukotriene receptor antagonist. Chest computed tomography revealed bronchial wall thickening and centrilobular nodules in the lower lobes of both lungs. Bronchoscopy showed obstruction of the subsegmental bronchus with mucus plugs. Histological analysis demonstrated abundant eosinophils in the mucus plugs. Cytolytic eosinophils together with Charcot–Leyden crystal formations and deposition of major basic proteins were also observed, indicating the occurrence of EETosis. Introduction of benralizumab, an anti-interleukin-5 receptor α antibody, successfully controlled the patient’s condition and reduced the amount of systemic corticosteroids administered. Our findings confirm that this antibody strongly decreases airway eosinophils in patients with severe asthma. Thus, benralizumab might be an optimal therapeutic agent for the treatment of mucus plug-forming and/or EETosis-occurring eosinophilic lung diseases, including eosinophilic bronchiolitis.


2022 ◽  
Vol 0 ◽  
pp. 1-4
Author(s):  
Nirma Joy

Calamine lotion is a shake lotion composed of calamine (zinc oxide/carbonate and ferric oxide), zinc oxide, bentonite, glycerine, sodium citrate, and liquified phenol. It is used widely in dermatology as a soothing agent. It is a preferred topical therapeutic agent for children including infants and is considered safe in pregnancy and lactation.


2022 ◽  
Author(s):  
Weilun Sun ◽  
Jingjing Xu ◽  
Bo Liu ◽  
Yuan-Di Zhao ◽  
Ling Yu ◽  
...  

Abstract Phage is a promising therapeutic agent for treating antibiotic resistant bacteria. However, in the process of treatment, phage may be cleared by the immune system and cleaved by protease, which could affect the efficacy of phage. In order to solve the above problems, phage encapsulation is usually adopted. In this study, we employed metal phenolic network (MPN) for efficient phage encapsulation which could protect phage from the cleavage of protease, and keep cytotoxicity weak. In the model of skin wound infection, the encapsulated phage could be released in response to pH change to achieve good antibacterial effect. Furthermore, the MPN encapsulation could prolong the T4 phage residence time at the wound. Our findings suggest that MPN can be a promising material for phage encapsulation.


Biomolecules ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 74
Author(s):  
Naofumi Amioka ◽  
Toru Miyoshi

Abdominal aortic aneurysm (AAA) is a life-threatening disease; however, there is no established treatment for patients with AAA. Fibrates are agonists of peroxisome proliferator-activated receptor alpha (PPARα) that are widely used as therapeutic agents to treat patients with hypertriglyceridemia. They can regulate the pathogenesis of AAA in multiple ways, for example, by exerting anti-inflammatory and anti-oxidative effects and suppressing the expression of matrix metalloproteinases. Previously, basic and clinical studies have evaluated the effects of fenofibrate on AAA. In this paper, we summarize the results of these studies and discuss the problems associated with using fenofibrate as a therapeutic agent for patients with AAA. In addition, we discuss a new perspective on the regulation of AAA by PPARα agonists.


Sign in / Sign up

Export Citation Format

Share Document